

# CardiologyRounds™

www.cardiologyrounds.org

AS PRESENTED IN THE ROUNDS OF THE CARDIOVASCULAR DIVISION  
OF BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MASSACHUSETTS

## Exercise intolerance and the role of exercise training in heart failure

By GARY J. BALADY, MD

Heart failure (HF) often leads to impaired exercise tolerance that incurs significant limitations in patients with this disability and, with the increased prevalence of HF, there are also important and widespread medical, social, and economic implications.<sup>1</sup> In patients with atherosclerotic cardiovascular disease, exercise training has been demonstrated to improve functional capacity and quality of life, reduce ischemia, and lower subsequent mortality.<sup>2,3</sup> Previously, exercise was proscribed in patients with HF; however, seminal data first published in the late 1980s sparked a remarkable interest in the application of exercise training to HF patients.<sup>4,5</sup> Recent studies demonstrating an improvement in functional capacity with exercise training in HF patients have led to the recognition that regular exercise can be a valuable adjunctive treatment strategy for stable HF patients. The application of exercise training as a therapeutic intervention has also yielded novel insights into the central and peripheral mechanisms of exercise intolerance. Accordingly, the American Heart Association recently published a comprehensive scientific statement on the topic of exercise and HF<sup>6</sup> that aims to stimulate the appropriate use of exercise training in HF patients and promote further research examining the many questions in this area that remain unanswered. The multicenter Heart Failure ACTION (A Controlled Trial Investigating Outcomes of exercise training) trial, recently funded by the National Institutes of Health, promises to provide information regarding the effect of exercise training on morbidity and mortality in HF patients. Since the bulk of the clinical data to date have included only patients with left ventricular systolic dysfunction, this issue of *Cardiology Rounds* will not discuss the topic of diastolic or preserved systolic function HF.

### Factors affecting exercise intolerance in heart failure

Exercise intolerance is often the initial presenting symptom in patients with left ventricular (LV) dysfunction and is a clinical hallmark of this condition. However, the pathophysiological basis for the development of limiting symptoms (eg, fatigue and dyspnea) remains somewhat controversial.<sup>7-12</sup> It is interesting (and somewhat surprising) that measures of the degree of LV systolic function (eg, ejection fraction) are only poorly correlated with exercise capacity.<sup>13,14</sup> Oxygen uptake ( $\text{VO}_2$ ) is considered to be the best measure of cardiovascular fitness and exercise capacity. Maximal oxygen consumption ( $\text{VO}_{2\text{max}}$ ) is the greatest amount of oxygen consumed from inspired air while performing dynamic exercise involving a large part of total muscle mass (from the Fick equation:  $\text{VO}_2 = \text{cardiac output} \times \text{arterio-venous oxygen difference}$ ).<sup>15</sup>

Each of the 3 systems participating in the exercise response – the central circulation, the peripheral vessels and skeletal muscles, and the ventilatory system – has been studied extensively.

### The central circulation

The central circulation in LV systolic dysfunction is characterized by inadequate LV shortening, increases in end-systolic and end-diastolic volume, and a decrease in ejection fraction. Secondary



BRIGHAM AND  
WOMEN'S HOSPITAL



HARVARD  
MEDICAL SCHOOL  
TEACHING AFFILIATE

### Cardiovascular Division (Clinical)

Michelle Albert, MD	Eldrin Lewis, MD
Elliott Antman, MD	James Liao, MD
Donald S. Baim, MD	Peter Libby, MD
Kenneth Baughman, MD	(Division Chief)
Joshua Beckman, MD	Leonard Lilly, MD
Gavin Blake, MD	Bernard Lown, MD
Charles M. Blatt, MD	William Maisel, MD
Eugene Braunwald, MD	Thomas Michel, MD, PhD
Christopher Cannon, MD	David Morrow, MD
Ming Hui Chen, MD	Karen Moulton, MD
Michael Chin, MD, PhD	Gilbert Mudge, MD
Mark Creager, MD	Anju Nohria, MD
Victor Dzau, MD	Patrick O'Gara, MD
Elazer Edelman, MD, PhD	Marc A. Pfeffer, MD, PhD
Andrew Eisenhauer, MD	(Editor)
Laurence Epstein, MD	Jorge Plutzky, MD
James Fang, MD	Jeffrey Popma, MD
Mark Feinberg, MD	Shmuel Ravid, MD
Jonas Galper, MD, PhD	Frederic Resnic, MD
Peter Ganz, MD	Paul Ridker, MD
J. Michael Gaziano, MD	Thomas Rocco, MD
Marie Gerhard-Herman, MD	Campbell Rogers, MD
Robert Giugliano, MD	Maria Ruppnick, MD, PhD
Michael Givertz, MD	Arthur Sasahara, MD
Samuel Z. Goldhaber, MD	S. Dinakar Satti, MD
Thomas B. Graboys, MD	Jay Schneider, MD
Howard Hartley, MD	Christine Seidman, MD
Carolyn Ho, MD	Andrew Selwyn, MD
Mukesh Jain, MD	Daniel Simon, MD
John Jarcho, MD	Laurence Sloss, MD
Paula Johnson, MD	Kyoko Soejima, MD
Ralph Kelly, MD	Regina Sohn, MD
Scott Kinlay, MD	Scott Solomon, MD
Jamil Kirdar, MD	Lynne Stevenson, MD
James Kirshenbaum, MD	William Stevenson, MD
Gideon Koren, MD	Peter Stone, MD
Richard Kuntz, MD	Michael Sweeney, MD
Raymond Kwong, MD	Frederick Welt, MD
Michael J. Landzberg, MD	Justina Wu, MD
Richard Lee, MD	


### Brigham and Women's Hospital

Fax: (617) 732-5291 Website: www.heartdoc.org

The editorial content of *Cardiology Rounds* is determined solely by the Cardiovascular Division of Brigham and Women's Hospital. This publication is made possible by an educational grant.

**Cardiology Rounds** is approved  
by the Harvard Medical School  
Department of Continuing Education  
to offer continuing education credit

**Figure 1: Comparison of cardiac output (C.O.) and arteriovenous oxygen difference (AVOD) during graded exercise in normal subjects (NL) and those with heart failure (HF)<sup>16</sup>**




pulmonary hypertension may result in right ventricular dysfunction and mitral regurgitation may arise from annular dilatation or papillary muscle dysfunction. Reduction in forward stroke volume coupled with a lower heart rate reserve (difference between resting and peak heart rate),<sup>4</sup> yield a lower cardiac output at submaximal and peak levels of effort (Figure 1).<sup>16</sup> In addition, diastolic dysfunction often accompanies systolic dysfunction and is characterized by an increased resistance to filling of one or both ventricular chambers. LV diastolic filling is governed by the pressure in the ventricular chamber, the LV compliance, and the duration of diastole. The normal left ventricle accomplishes a higher diastolic filling rate during exercise by increasing its distensibility, thus increasing LV diastolic volume without raising its pressure. Patients with LV diastolic dysfunction have an impaired ability to increase ventricular distensibility with exercise, thus leading to a rapid rise in LV diastolic pressure and pulmonary capillary wedge pressure, and hence, exercise-limiting dyspnea.

### The periphery

The “periphery” is abnormal in patients with LV systolic dysfunction with changes observed in peripheral vascular tone, as well as in the structure and function of skeletal muscle. During maximal exercise testing, patients typically report leg fatigue. This fatigue is associated with a greater release of lactate from the legs, thus providing objective evidence of muscle dysfunction. The degree of abnormality in lactate relates closely to maximal exercise capacity, suggesting

**Figure 2: Changes in TNF-alpha and soluble Fas ligand are inversely related to changes in exercise capacity in subjects with heart failure. These markers are reduced as exercise capacity increases.<sup>27</sup>**



a close link between muscle dysfunction and exercise intolerance in HF. Duscha et al noted that skeletal muscle abnormalities in heart failure patients are beyond that which would ordinarily exist in sedentary individuals and they defined this as a state of “ultraconditioning.”<sup>17</sup> This skeletal muscle dysfunction may be due, in part, to inadequate blood flow, since 50% to 60% of HF patients have lower than normal blood flow to the legs during exercise. In the remaining patients, blood flow during exercise is within the normal range, although muscle lactic acid release is impaired.<sup>18</sup> Intrinsic skeletal muscle abnormalities have been described in HF patients despite normal limb blood flow and oxygenation. Muscle biopsy studies have demonstrated reduced mitochondrial-based enzymes, reduced mitochondrial size, decreased Type II muscle fiber size, and an increase in the percentage of type II fibers.<sup>18-22</sup> Using phosphorus nuclear magnetic resonance spectroscopy, a number of investigators have demonstrated that the metabolic responses of both the forearm and calf muscles to exercise are altered in HF patients. Phosphocreatine depletion is more rapid, resynthesis of high-energy compounds (phosphocreatine and ATP) is delayed, and there is an earlier development of acidosis in these patients.<sup>23</sup> These abnormalities may be attributed to higher levels of inducible nitric oxide synthase (iNOS) in the skeletal muscles of HF patients. iNOS appears to attenuate mitochondrial energy transfer by reducing muscle creatine kinase. It has been demonstrated that exercise capacity is inversely related to iNOS levels and positively related to creatine kinase levels.<sup>24</sup>

Skeletal muscle mass of the lower extremities, measured using thigh cross-sectional area, has a modest correlation with peak exercise capacity.<sup>25</sup> Reduced skeletal muscle mass has been demonstrated in HF patients and becomes more apparent as the severity of HF increases.<sup>26</sup> Although this finding may be attributed, in part, to the disuse atrophy of a sedentary lifestyle, emerging data provide further explanations. Higher levels of apoptotic mediators<sup>27</sup> and lower levels of insulin-like growth factors (IGF-1)<sup>28</sup> in the skeletal muscles of HF patients may further contribute to their observed reduced muscle mass and ultraconditioned state (Figure 2). Notably, HF patients with reduced lower limb muscle mass also have lower IGF-1 levels.<sup>28</sup>

## The ventilatory system

The ventilatory system also demonstrates a wide range of changes in patients with LV systolic dysfunction, including structural abnormalities (pulmonary damage and fibrosis) and dynamic changes (eg, skeletal muscle fatigue).<sup>29</sup> However, it appears clear that ventilatory abnormalities do not limit peak exercise performance in most HF patients. Ventilatory reserve is high,<sup>30</sup> arterial O<sub>2</sub> and CO<sub>2</sub> concentrations remain normal,<sup>5</sup> the anaerobic threshold occurs early during progressive exercise testing,<sup>31</sup> systemic and regional venous oxygen desaturation are maximal,<sup>4</sup> and VO<sub>2</sub> often plateaus — all suggesting circulatory rather than pulmonary limitations.

## The role of exercise training

### Central effects

Although pharmacologic therapy is the cornerstone in the treatment of HF, exercise training can be an important adjunctive therapeutic modality in stable patients. Exercise training in apparently healthy persons alters maximal oxygen uptake, central hemodynamic function, autonomic nervous system function, peripheral vascular and muscular function, as well as submaximal exercise capacity. Collectively, these adaptations result in an exercise *training effect* that allows an individual to exercise to higher peak workloads with lower heart rates at each submaximal level of exercise.<sup>15</sup> To date, there are more than 30 published studies collectively involving several hundred HF patients that have evaluated the efficacy of exercise training. Improvements of 18%-25% in peak oxygen uptake and 18%-34% in peak exercise duration have been attained (Table 1). Subjective symptoms, activity profile, and quality of life scores have also improved after training.<sup>32</sup> Most exercise-training studies in patients with HF have generally employed moderate to high intensity exercise (70%-80% peak heart rate). However, two studies have demonstrated significant improvements in peak oxygen uptake and peak work rate after 8-12 weeks of lower intensity training (40%-50% of peak VO<sub>2</sub>).<sup>22,23</sup>

Exercise training does not appear to improve cardiac output during submaximal exercise in patients with LV dysfunction.<sup>22,34,35</sup> Most studies show no change in resting ejection fraction, although one study demonstrated that with peak levels of exercise, cardiac output is slightly increased.<sup>34</sup> The ventilatory anaerobic threshold, an objective, non-volitional measure of cardiovascular fitness, is delayed after training and occurs at a higher O<sub>2</sub> consumption.<sup>32,34</sup> Pulmonary artery pressure, pulmonary capillary wedge pressure, and systemic vascular resistance are usually unchanged after training either at rest or during exercise.<sup>32,34</sup> One study has demonstrated that HF patients with an impaired cardiac output response to exercise, usually do not improve their functional capacity with exercise training.<sup>36</sup> Although the use of invasive hemodynamic assessment in the large number of patients with LV dysfunction precludes broad screening of these patients prior to exercise training, further research in this area, perhaps using non-invasive determinants of exercise cardiac output, may offer additional insight into this potentially important observation.

**Table 1: Studies on exercise training in chronic heart failure**


Author	Year	N	EF (%)	Intensity
Conn, et al <sup>51</sup>	1982	10	29	70%-80% HR
Sullivan, et al <sup>5</sup>	1988	12	24	75% VO <sub>2</sub>
Jette, et al <sup>52</sup>	1991	7	24	70%-80% HR
Meyer, et al <sup>53</sup>	1991	12	23	70 – 80% HR
Coats, et al <sup>32</sup>	1992	17	19	70%-80% HR
Koch, et al <sup>54</sup>	1992	12	26	Individualized protocol
Belardinelli, et al <sup>22</sup>	1995	16	31	40% VO <sub>2</sub>
Belardinelli, et al <sup>37</sup>	1995	36	28	60% VO <sub>2</sub>
Hambrecht, et al <sup>19</sup>	1995	12	26	70% VO <sub>2</sub>
Keteyan, et al <sup>55</sup>	1996	15	21	60%-80% HR
Kavanaugh, et al <sup>56</sup>	1996	15	22	50%-60% VO <sub>2</sub>
Kilavuori, et al <sup>57</sup>	1996	12	24	50%-60% VO <sub>2</sub>
Wilson, et al <sup>36</sup>	1996	32	23	60-70% HR
Demopoulos, et al <sup>33</sup>	1997	16	21	50%-80% VO <sub>2</sub>
Dubach, et al <sup>35</sup>	1997	12	32	70%-80% VO <sub>2</sub>
Meyer, et al <sup>58</sup>	1997	18	21	50% VO <sub>2</sub>
European Heart Failure Training Group <sup>59</sup>	1998	134	25	70%-80% HR
Hambrecht, et al <sup>39</sup>	1998	10	24	70% VO <sub>2</sub>
Benardinelli, et al <sup>60</sup>	1999	50	28	60% VO <sub>2</sub>
Braith, et al <sup>43</sup>	1999	10	30	70%-80% VO <sub>2</sub>
Hambrecht, et al <sup>61</sup>	2000	73	27	70% VO <sub>2</sub>
McKelvie, et al <sup>62</sup>	2002	181	<40	70% VO <sub>2</sub> and resistance training
Adamopoulos, et al <sup>27</sup>	2002	24	23	60%-80% HR

The effects of exercise training on LV diastolic function have not been well studied. In patients with systolic dysfunction, LV diastolic wall stress has been shown to be significantly lower during exercise at low work rates (50% peak VO<sub>2</sub>), than that during conventional work rates (70%-80% peak VO<sub>2</sub>). Such training at the lower work rate yielded a 30% increase in peak VO<sub>2</sub> after 2 months.<sup>33</sup> Another study demonstrated that among patients with dilated cardiomyopathy and a Doppler mitral inflow profile suggestive of concomitant abnormal diastolic LV function, only those with delayed relaxation improved their functional capacity after training. In these latter patients, the diastolic filling pattern normalized after training. In contrast, those with a restrictive filling pattern were found to have a worse prognosis and did not improve functional capacity or diastolic filling pattern after training.<sup>37</sup>

### Peripheral effects

Skeletal muscle abnormalities found in HF patients can be reversed with exercise training.<sup>20,21,32</sup> Exercise training can improve the volume density of mitochondria and the volume density of cytochrome-c oxidase-positive mitochondria with an increase expression of enzymes for oxidative metabolism.<sup>19,20,22,32</sup> Peak exercise leg blood flow and leg arteriovenous oxygen difference appear to increase after training.<sup>34</sup>


**Figure 3: Brachial artery flow-mediated dilation (blue bars) is impaired in subjects with heart failure (CHF) compared to normal subjects, and improved after training (CHF trained). Flow-mediated dilation (gray bars) is attenuated after administration of L-NMMA in all subjects.<sup>38</sup>**



Improvement in endothelial function has been suggested as a possible mechanism for these findings and is an area of great research interest. Using measures of brachial artery flow-mediated dilation to assess endothelial function, forearm blood flow has been shown to normalize after local forearm muscle training in HF patients. This improvement is attenuated by local administration of N<sup>G</sup>-monomethyl-L-arginine (L-NMMA) that blocks nitric oxide synthesis, thus indicating that the positive effects of exercise training on vascular function are at least, in part, mediated by nitric oxide (Figure 3).<sup>38</sup> Similarly, femoral artery flow responses to acetylcholine have been shown to improve in patients with HF after cycle exercise training, compared to sedentary control subjects. These improvements in flow responses show a modest positive correlation with improvements in peak VO<sub>2</sub> after training.<sup>39</sup> Further, exercise studies in patients without HF indicate that systemic improvements in endothelial function occur after training, as improved flow responses to acetylcholine are seen in non-trained limbs<sup>40</sup> and in diseased coronary arteries.<sup>41</sup>

Increased plasma catecholamines have been associated with a poor prognosis in patients with HF. Although results are variable, most studies demonstrate the beneficial effects of enhanced vagal tone and decreased sympathetic tone after exercise training.<sup>32,42</sup> Baroreflex dysfunction and renal hypoperfusion in HF patients lead to increased levels of the neurohormones (angiotensin, aldosterone, vasopressin, and atrial natriuretic peptide). One study demonstrated that dynamic exercise training buffers this neurohormonal hyperactivity (Figure 4).<sup>43</sup> Controlled trials of exercise training also demonstrate reduced levels of the inflammatory cytokines (eg, tumor necrosis factor alpha [TNF- $\alpha$ ] and interleukin-6 [IL-6]), in HF patients after training.<sup>27</sup> Whether these positive effects of exercise training on autonomic tone, neurohormones, and inflammatory cytokine levels actually yield benefits for the HF patient is not yet known. These results signal that the beneficial effects of exercise

**Figure 4: Angiotensin II levels are increased in subjects with heart failure (HF) compared to normal subjects (NL), and are reduced in heart failure subjects after exercise training (HF trained).<sup>43</sup>**



HT = heart transplant patients

training may likely extend beyond improvements in exercise tolerance.

### Risks of exercise training in patients with heart failure

Individuals with cardiac disease appear to be at an increased risk for sudden cardiac arrest during vigorous exercise (eg, jogging) than healthy individuals.<sup>15</sup> The incidence of major cardiovascular complications during outpatient cardiac rehabilitation exercise programs has been estimated to be 1 in 60,000 participant-hours.<sup>44</sup> Patients with chronic HF have a greater overall morbidity and mortality than that of healthy persons and those with other forms of heart disease. Thus, current practice guidelines stratify HF patients at the highest level of risk.<sup>15,45,46</sup> However, exercise-training studies of patients with HF (Table 1) demonstrate that the overall adverse event rate appears to be low. Hypotension after exercise, atrial and ventricular arrhythmias, and worsening of HF symptoms are the most commonly reported adverse events. Remarkably, the adverse event rates in studies of HF patients who performed home exercise is also low.<sup>19,32,39</sup> The Heart Failure ACTION trial promises to provide important information regarding the risks of moderate-intensity exercise in HF patients, and adverse event rates relative to the level of supervision during training.

LV remodeling is a dynamic process that occurs after acute myocardial infarction (MI), and can affect the size and shape of the left ventricle. Concerns have been raised about the possible detrimental effects of exercise training on LV remodeling in patients after MI. Although no studies have specifically addressed this issue in HF patients, a single, small, non-randomized study has shown that patients after first anterior Q wave infarction with >18% asynergy, experienced a further increase in asynergy and a decrease in ejection fraction after

12 weeks of exercise training when compared to non-exercising controls.<sup>47</sup> However, 2 subsequent randomized controlled trials of moderate- to high-intensity exercise-training patients after a large MI have not demonstrated adverse effects on regional wall motion, LV systolic function, or LV chamber dimensions after several months of exercise.<sup>48,49</sup> The Exercise in Anterior MI (EAMI) trial showed that among patients with ejection fraction <40%, spontaneous global and regional LV dilatation occurred similarly in both the exercise and control groups, but was not influenced by exercise training.<sup>48</sup> In another study<sup>49</sup> of 25 patients with an average ejection fraction of 32%, using serial LV measurements obtained from magnetic resonance imaging, no detrimental effects on LV volumes or ejection fraction were seen after 2 months of moderate-intensity cycle exercise training.

## Conclusion

The American Heart Association<sup>6,50</sup> and the American College of Cardiology<sup>50</sup> conclude that the data regarding exercise in HF offer important evidence for encouraging its broader application among this rapidly enlarging population of patients. However, further studies are needed to evaluate the safety and effectiveness of exercise-training prescriptions. More information is needed concerning the role and efficacy of resistance training, the effects of exercise on prognosis, as well as the efficacy of exercise programs in patients with HF from causes other than coronary artery disease (ie, valvular regurgitation and other cardiomyopathies). The Heart Failure ACTION trial is designed to provide important information regarding the effect of exercise on morbidity and mortality, as well as the risks of supervised and unsupervised exercise in HF patients. Substudies of this trial will provide further insights into the mechanisms of exercise intolerance in HF and the effects of exercise training in modulating these responses.

## References:

- American Heart Association Heart Disease and Stroke Statistics. 2003 Update. www.americanheart.org. Accessed May 9, 2003.
- Balady GJ, Fletcher BJ, Froelicher EF, et al. Statement of cardiac rehabilitation programs. American Heart Association. *Circulation* 1994;90:1602-1610.
- U.S. Department of Health and Human Services. Agencies for Health Care Policy and Research. Clinical Practice Guideline Number 17. *Cardiac Rehabilitation*. October, 1995. AHCPR Publication No. 96-0672.
- Sullivan MJ, Knight B, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with severe heart failure. *Circulation* 1989;80:769-781.
- Sullivan MJ, Higginbotham MB, Cobb FR. Increased exercise ventilation in patients with chronic heart failure: intact ventilatory control despite hemodynamic and pulmonary abnormalities. *Circulation* 1988;77:552-559.
- Pina IL, Apstein CS, Balady GJ, et al. Exercise and Heart Failure: a statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention. *Circulation* 2003;107: 1210-1225.
- Weber KP, Kinasewitz GT, Janicki JS, Fishman AP. Oxygen utilization during exercise in patients with chronic cardiac failure. *Circulation* 1982;65:1213-1223.
- Weber KP, Wilson JR, Janicki JS, Likoff MJ. Exercise testing in the evaluation of patients with chronic cardiac failure. *Am Rev Respir Dis* 1984;129:S60-S62.
- LeJemthel TH, Liang CS, Stewart DK, et al. Reduced peak aerobic capacity in asymptomatic left ventricular systolic dysfunction. *Circulation* 1994;90:2757-2760.
- Wilson KR, Martin JL, Schwartz D, Ferraro N. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. *Circulation* 1984;69:1079-1087.
- Mancini DM, Walter G, Reichek N, et al. Contribution of skeletal muscle atrophy due to exercise intolerance and altered muscle metabolism in heart failure. *Circulation* 1992;85:1364-1373.

- Kramer MD, Kubo SH, Rector TS, Brunsvold N, Bank AJ. Pulmonary and peripheral vascular factors are important determinants of peak exercise oxygen uptake in patients with heart failure. *J Am Coll Cardiol* 1993;21:641-648.
- Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. *Am J Cardiol* 1981;47:33-39.
- Fleg JL, O'Connor F, Gerstenblith G, et al. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. *J Appl Physiol* 1995;78:890-900.
- Fletcher G, Balady GJ, Amsterdam E, et al. Exercise Standards for Testing and Training. A Statement from the American Heart Association. *Circulation* 2001; 104:1694-1740.
- Roubin GS, Anderson SD, Shen WF, et al. Hemodynamic and metabolic basis of impaired exercise tolerance in patients with severe left ventricular dysfunction. *J Am Coll Cardiol* 1990;15:986-994.
- Duscha BD, Annex BH, Green HJ, Phippen AM, Kraus WE. Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure. *J Am Coll Cardiol* 2002;39:1170-1174.
- Massie BM, Conway M, Rapagopal B, et al. Skeletal muscle metabolism during exercise under ischemic conditions in congestive heart failure. *Circulation* 1988;78:320-326.
- Hambrecht R, Neibauer J, Fiehn E, et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. *J Am Coll Cardiol* 1995;25:1239-1249.
- Adamopoulos S, Coats AJS, Brunotte F. Physical training improves skeletal muscle metabolism in patients with chronic heart failure. *J Am Coll Cardiol* 1993;21:1101-1106.
- Mancini DM, Colye E, Coggan A et al. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. *Circulation* 1989;80:1338-1346.
- Belardinelli R, Georgiou D, Scozzo V, Barstow TJ, Purcaro A. Low intensity exercise training in patients with chronic heart failure. *J Am Coll Cardiol* 1995; 26:975-982.
- Wilson JR, Mancini DM. Skeletal muscle metabolic dysfunction: implications for exercise intolerance in heart failure. *Circulation* 1993;87 ( suppl VII):VII-104-109.
- Hambrecht R, Adams V, Gielen S, et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. *J Am Coll Cardiol* 1999;33:174-179.
- Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. *J Am Coll Cardiol* 1997;30: 1758-1764.
- Pu C, Johnson M, Forman DE, et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. *J Appl Physiol* 2001;90:2341-2350.
- Adamopoulos S, Parissis J, Karatzas D, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. *J Am Coll Cardiol* 2002;39:653-663.
- Hambrecht R, Schulze C, Gielen S, et al. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. *J Am Coll Cardiol* 2002;39:1175-1181.
- Mancini DM. Pulmonary factors limiting exercise capacity in patients with heart failure. *Prog Cardiovasc Dis* 1995;37:347-370.
- Wassermann K. Dyspnea on exertion: Is it the heart or the lungs? *JAMA* 1982; 248:2039-2043.
- Simonton CA, Higginbotham NB, Cobb FR. The ventilatory threshold: quantitative analysis of reproducibility and relation to arterial lactate concentration in normal subjects and in patients with chronic congestive heart failure. *Am J Cardiol* 1988;62:100-107.
- Coats AJS, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. *Circulation* 1992;85:2119-2131.
- Demopoulos L, Bijou R, Fergus I, Jones M, Strom J, LeJemthel G. Exercise training in patients with severe congestive heart failure: enhancing peak aerobic capacity while minimizing the increase in ventricular wall stress. *J Am Coll Cardiol* 1997;29:597-603.
- Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction; hemodynamic and metabolic effects. *Circulation* 1988;78:506-515.
- Dubach P, Myers J, Dziekan G, et al. The effect of high intensity exercise training on central hemodynamic response to exercise in men with reduced left ventricular function. *J Am Coll Cardiol* 1997;29:1591-1598.
- Wilson JR, Groves J, Rayos G. Circulatory status and response to cardiac rehabilitation in patients with heart failure. *Circulation* 1996;94:1567-1572.
- Belardinelli R, Georgiou G, Cianci G, Berman N, Ginzton L, Purcaro A. Exercise training improves LV diastolic filling in patients with dilated cardiomyopathy. *Circulation* 1995;91:2775-2784.
- Hornig B, Maier V, Drexler H. Physical training improves endothelial functioning in patients with chronic heart failure. *Circulation* 1996;93:210-214.
- Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. *Circulation* 1998;98:2709-2715.
- Linke A, Schoene N, Gielen S, et al. Endothelial dysfunction in patients with chronic heart failure: systemic effects of lower-limb exercise training. *J Am Coll Cardiol* 2001;37:392-397.
- Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. *N Engl J Med* 2000;342: 454-460.
- Kilavuori K, Naveri H, Leinonen H, et al. The effect of physical training on hormonal status and exertional hormonal response in patients with chronic congestive heart failure. *Eur Heart J* 1999;20:456-464.

43. Braith RW, Welsch M, Feigenbaum MS, Kluess HA, Pepine CJ. Neuro-endocrine activation in heart failure is modified by endurance exercise training. *J Am Coll Cardiol* 1999;34:1170-1175.
44. Franklin BA, Bonzheim K, Gordon S, et al. Safety of medically supervised cardiac rehabilitation therapy: a 16-year follow-up. *Chest* 1998;114:902-906.
45. Franklin B, (Ed). *American College of Sports Medicine Guidelines for Exercise Testing and Prescription*. (6th Edition) New York: Williams and Wilkins; 2000.
46. Williams M, (Ed). American Association for Cardiovascular and Pulmonary Rehabilitation. *Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs*. Champaign, Ill: Human Kinetics Publishers; 1999.
47. Jugdutt BI, Michorski BL, Kappagoda CT. Exercise training after anterior Q wave myocardial infarction. *J Am Coll Cardiol* 1988;12:362-372.
48. Giannuzzi P, Tavazzi L, Temporelli PL, et al. Long-term physical training and left ventricular remodeling after anterior myocardial infarction: results of the exercise in anterior myocardial infarction (EAMI) trial. *J Am Coll Cardiol* 1993;22:1821-1829.
49. Dubach P, Myers J, Dziekn G, et al. The effect of exercise training on myocardial remodeling in patients with reduced left ventricular function after myocardial infarction. *Circulation* 1997;95:2060-2067.
50. Hunt SA, Baker DW, Chin MH, et al. American College of Cardiology/ American Heart Association Guidelines on the evaluation and management of heart failure in the adult Committee to revise the 1995 guidelines for the evaluation and management of heart failure. Available at: [www.acc.org/clinical/guidelines/failure/hf\\_index.htm](http://www.acc.org/clinical/guidelines/failure/hf_index.htm). Accessed: May 9, 2003.
51. Conn EH, Williams RS, Wallace AG. Exercise responses before and after physical conditioning in patients with severely depressed left ventricular function. *Am J Cardiol* 1982;49:296-300.
52. Jette M, Heller R, Landry F, Blumchen G. Randomized four-week exercise program in patients with impaired left ventricular function. *Circulation* 1991;84:1561-1567.
53. Meyer TE, Casadei B, Coats AJS. Angiotensin-converting enzyme inhibition and physical training in heart failure. *J Intern Med* 1991;230:407-413.
54. Koch M, Douard H, Broustet JP. The benefit of graded physical exercise in chronic heart failure. *Chest* 1992;101:231S-234 S.
55. Keteyian S, Levine A, Brawner CA, et al. Exercise training in patients with heart failure: a randomized, controlled trial. *Ann Int Med* 1996;124:1051-1057.
56. Kavanagh T, Myers MG, Baigrie RS, Mertens DJ, Sawyer P, Shephard RJ. Quality of life and cardiorespiratory function in chronic heart failure: effects of 12 months aerobic training. *Heart* 1996;76:42-49.
57. Kiilavuori K, Sovijarvi A, Naveri H, Ikonen T, Leinonen H. Effect of physical training on exercise capacity and gas exchange in patients with chronic heart failure. *Chest* 1996;110:985-991.
58. Meyer K, Schwaibold M, Westbrook S, et al. Effects of exercise training and activity restriction on 6-minute walking test performance in patients with chronic heart failure. *Am Heart J* 1997;133:447-53.
59. European Heart Failure Training Group. Experience from controlled trials of physical training in chronic heart failure. *Eur Heart J* 1998;19:466-475.
61. Hambrecht R, Gielen S, Linke A, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trail. *JAMA* 2000;283:3095-3101.
62. McKelvie RS, Kook T, Roberts R, et al. Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). *Am Heart J* 2002;144:23-30.



**Dr. Gary J. Balady** is a Professor of Medicine at Boston University School of Medicine, the Director of Preventive Cardiology, and Co-Director of the Non-Invasive Cardiac Laboratories. Dr. Balady is a Fellow of the American Heart Association, the American College of Cardiology, and the American Association of Cardiovascular and Pulmonary Rehabilitation. Dr. Balady serves the American Heart Association both nationally and locally by leading and/or participating on several key committees involved with exercise, physical activity, and preventive cardiology. He is currently the Chairman of the Council on Clinical Cardiology, the largest scientific council of the AHA. He has been a member of several writing groups of the American Heart Association and American College of Cardiology, which

generate guidelines regarding exercise testing and training. Dr. Balady's research interests focus on exercise testing and training of cardiac patients, with a particular emphasis on the physiologic changes that occur in the cardiovascular system with regular exercise. He is Editor-in-Chief of the *Journal of Cardiopulmonary Rehabilitation*, and serves on the Editorial Board of the *American Journal of Cardiology* and the *Journal of Noninvasive Cardiology*.

*Dr. Gary Balady has no disclosures to announce related to the enclosed CME program.*



**Harvard Medical School**

Department of Continuing Education  
and



**Brigham and Women's Hospital**

Cardiovascular Division

present

## Thrombosis and Thromboembolism

October 16-17, 2003

in Boston at the  
Fairmont Copley Plaza Hotel

### Course Directors:

Samuel Z. Goldhaber, MD Paul M Ridker, MD

To register or view course details online visit us at:  
[www.cme.med.harvard.edu/thrombosis](http://www.cme.med.harvard.edu/thrombosis)

For more information regarding registration: Call:

**617-384-8600**

Monday - Friday, 10 AM to 4 PM EST

Mail: Harvard MED-CME,

P.O. Box 825, Boston, MA 02117

Email: [hms-cme@hms.harvard.edu](mailto:hms-cme@hms.harvard.edu)

Tuition: \$395 (U.S.)

Residents and Fellows in Training: \$295 (U.S.)\*

\*A letter of verification from Department Chairman must accompany application for a reduced fee.

For information regarding course content, call:

**617-732-7566**

Brigham and Women's Hospital,  
Cardiovascular Division website:

[www.heartdoc.org](http://www.heartdoc.org)

This publication is made possible by an educational grant from

# Novartis Pharmaceuticals Corporation

© 2003 Brigham and Women's Hospital, Boston, Massachusetts, which is solely responsible for the contents. The opinions expressed in this publication do not necessarily reflect those of the publisher or sponsor, but rather are those of the author based on the available scientific literature. Publisher: **SNELL Medical Communication Inc.** in cooperation with Brigham and Women's Hospital, Boston, Massachusetts. <sup>TM</sup>*Cardiology Rounds* is a Trade Mark of SNELL Medical Communication Inc. All rights reserved. The administration of any therapies discussed or referred to in *Cardiology Rounds* should always be consistent with the recognized prescribing information as required by the FDA. **SNELL Medical Communication Inc.** is committed to the development of superior Continuing Medical Education.